Evidence map›Paper›PMID 40375799›Full record

ReviewEpigenomics2025

Resolving sequencing-based HIV-1 epitranscriptomics.

Michael S Bosmeny, Joao I Mamede, Keith T Gagnon

Abstract readReview
In one paragraph

Review in Epigenomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Michael S BosmenyDepartment of Biochemistry, Wake Forest University, School of Medicine, Winston-Salem, NC, USA.
Joao I MamedeDepartment of Microbial Pathogens and Immunity, Rush University, Chicago, IL, USA.
Keith T GagnonDepartment of Biochemistry, Wake Forest University, School of Medicine, Winston-Salem, NC, USA.ORCID 0000-0002-5868-675X

Funding

Coupling Epitranscriptomics to Molecular Disease Mechanisms and Nucleic Acid Therapeutics in Persistent Residual HIV InfectionR61AI169661 · NIAID · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI GAGNON, KEITH THOMAS · 2022 to 2024
$1.8M
Coupling Epitranscriptomics to Molecular Disease Mechanisms and Nucleic Acid Therapeutics in Persistent Residual HIV InfectionR33AI169661 · NIAID · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Keith Thomas Gagnon · 2025 to 2026
$1.5M
NIAID NIH HHS R33 AI169661NIAID NIH HHS R61 AI169661
6 · The paper itself

Abstract

The collection of HIV-1 RNA chemical modifications and their functional consequences in viral gene expression, host interactions, and the viral life cycle, referred to as HIV-1 epitranscriptomics, remain incompletely understood. While the field is evolving, diverse modification discovery methods, cell lines, HIV-1 sequences, and bioinformatics methods make a consensus view of the HIV-1 epitranscriptome difficult to resolve. Here, we review methods for identifying and interpreting N

Indexed as

Epigenesis, GeneticHIV-1HIV InfectionsRNA, ViralTranscriptomeEpigenomicsHumansSequence Analysis, RNARNA, ViralepitranscriptomicsHIV-1nanoporeRNA modificationsequencing

Identifiers

PMID40375799
PMCPMC12140454

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.